Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Neurology"
DOI: 10.1001/jamaneurol.2017.1912
Abstract: Importance Neurological complications are an increasingly recognized consequence of the use of anti–programmed death 1 (PD-1) antibodies in the treatment of solid-organ tumors, with an estimated frequency of 4.2%. To date, the clinical spectrum and… read more here.
Keywords: anti therapy; treatment; neurological complications; associated anti ... See more keywords
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.0051
Abstract: Importance Agents targeting programmed cell death 1 (PD-1)/PD ligand 1 (PD-L1) improve long-term survival across many advanced cancers and are now used as adjuvant therapy for resected stage III and IV melanomas. The incidence and… read more here.
Keywords: chronic immune; anti therapy; immune related; therapy ... See more keywords
Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti-PD-1 Therapy.
Sign Up to like & getrecommendations! Published in 2025 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2024.6168
Abstract: This cohort study examines the response and survival rates associated with ipilimumab-nivolumab therapy in patients with progressive melanoma brain metastases after anti–programmed cell death 1 (anti–PD-1) therapy. read more here.
Keywords: brain metastases; therapy; anti therapy; melanoma brain ... See more keywords
Blocking ITGA5 potentiates the efficacy of anti‐PD‐1 therapy on glioblastoma by remodeling tumor‐associated macrophages
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Communications"
DOI: 10.1002/cac2.70016
Abstract: Glioblastoma (GBM) is largely refractory to antibodies against programmed cell death 1 (anti‐PD‐1) therapy. Fully understanding the cellular heterogeneity and immune adaptations in response to anti‐PD‐1 therapy is necessary to design more effective immunotherapies for… read more here.
Keywords: potentiates efficacy; therapy; itga5 potentiates; anti therapy ... See more keywords
SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy.
Sign Up to like & getrecommendations! Published in 2019 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2019.105818
Abstract: Immune checkpoint inhibitors, such as anti-PD-1/PD-L1, are a novel class of inhibitors that function as a tumor suppressing factor via modulation of immune cell-tumor cell interaction. To date, PD-1/PD-L1 inhibitors have been approved for the… read more here.
Keywords: suppressor cells; anti therapy; derived suppressor; response anti ... See more keywords
Wong-type dermatomyositis during anti–PD-1 therapy
Sign Up to like & getrecommendations! Published in 2018 at "JAAD Case Reports"
DOI: 10.1016/j.jdcr.2018.08.006
Abstract: Checkpoint inhibitors used for cancer immunotherapy may also result in autoimmunity.1, 2 We present a case of Wong-type dermatomyositis complicating treatment with nivolumab, an inhibitor of the programmed cell death 1 (PD-1) receptor. Wong-type dermatomyositis… read more here.
Keywords: anti therapy; type dermatomyositis; dermatomyositis anti; dermatomyositis ... See more keywords
Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of ethnopharmacology"
DOI: 10.1016/j.jep.2021.114370
Abstract: ETHNOPHARMACOLOGICAL RELEVANCE The programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint is one of the most promising therapeutic targets for cancer immunotherapy, but several challenges remain in current anti-PD-1/PD-L1 therapy. Natural products,… read more here.
Keywords: medicine; anti therapy; natural products; traditional medicines ... See more keywords
Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.04.022
Abstract: OBJECTIVE Serum adenosine deaminase (ADA) activity is a marker of immune reaction to several diseases. We evaluated changes in serum ADA in patients with lung cancer undergoing chemotherapy or anti-programmed cell death-1 (PD-1) therapy to… read more here.
Keywords: efficacy; serum ada; anti therapy; therapy ... See more keywords
Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.10.023
Abstract: BACKGROUND Tobacco exposure contributes to over 80 % of lung cancer cases. Smoking is associated with programmed death-ligand 1 (PD-L1) tumor expression and better outcomes from anti-programmed cell death protein 1 (anti-PD-1) therapy in patients… read more here.
Keywords: anti therapy; response; expression; tobacco exposure ... See more keywords
Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma.
Sign Up to like & getrecommendations! Published in 2020 at "Vaccine"
DOI: 10.1016/j.vaccine.2020.06.055
Abstract: BACKGROUND Targeting antigens to dendritic cells (DCs) via nanoparticles is a powerful strategy which improves the efficacy of ex vivo antigen-pulsed DC vaccines. METHODS In this study, liposomes were first decorated with gp10025-33 self-antigen and… read more here.
Keywords: anti therapy; gp100; pulsed vivo; dendritic cells ... See more keywords
Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial
Sign Up to like & getrecommendations! Published in 2025 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-025-02460-z
Abstract: Local consolidative therapy (LCT) has been demonstrated to enhance the survival benefits of immunotherapy in non-small cell lung cancer (NSCLC) patients with oligometastatic or oligoprogressive disease. This randomized, phase 2 trial investigated the efficacy and… read more here.
Keywords: disease; therapy; immunotherapy; anti therapy ... See more keywords